University of Thessaly (UTH)
Μελέτη της ομοιοστασίας των Β λεμφοκυττάρων στη συστηματική σκλήρυνση
Abstract
dc:descriptionIntroduction: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by microvasculopathy, autoantibodies (autoAbs), and excessive collagen deposition. The pathogenesis of this disease is incompletely understood and the clinical manifestations vary. B cells play an important role in its pathogenesis. Our clinic reported a reduction of regulatory B cells in SSc, that results in reduced inhibitory effects on B effector cells. CD21low B cells are increased in many autoimmune diseases and were reported to include autoreactive cells. Aim: The aim of our study was to study the significance of CD21low B lymphocytes in SSc. Therefore, we studied CD21low B cells and their relation to the main aspects of the disease. We also studied CD32 receptors of B cells (B lymphocytes express almost exclusively, one of the three isoforms of the CD32 receptor, the inhibitor FcγRIIB isoform), and B cells that recognize Topoisomerase I (Topo I). Patients: Our study included twenty-seven patients (21 women, median age 55,6 years, 7 men, median age 59,5 years), followed up in the Outpatient Clinic of the Department of Rheumatology and clinical Immunology of the University General Hospital of Larissa, and 15 age-and sex-matched healthy controls (HCs). Patients were fulfilling the ACR / EULAR 2013 criteria for SSc. All participants gave their informed consent. The study was carried out after the approval of the ethics committee. Methods: Mononuclear cells were isolated from20 mL of peripheral blood after centrifugation in Ficoll and B cell surface markers were detected using multicolor flow cytometry with the monoclonal antibodies anti-CD19, anti-CD27, anti-CD32 (which recognizes both isoforms FcγRIIA and FcγRIIB) and anti-CD21. In addition, recombinant Topo I was APC-conjugated to detect B cells recognizing Topo I. Results: Fourteen patients had a history or active digital ulcer, 10 patients had interstitial lung disease and 17 patients had anti-Topo I antibodies. The percentage of CD21low B cells was significantly increased in patients with DUs (51.33%) compared to HCs (28.15%, p=0.014) and to patients without DUs (29.34%, p=0.042) and in patients with Interstitial Lund Disease (ILD) (53.1%) compared to HCs (28.1% p=0.014). There was no statistically significant difference of CD21low B cells between the ILD group and the non-ILD (33.47%, p=0.08). The percentage of CD21low B cells in the anti-Topo I-positive patient group (48.6%), was significantly increased compared to anti-Topo I-negative patient group (27.3%, p=0.025), but not significantly so compared to HCs (28.1%, p= 1.1). CD21low B cells were not significantly increased in SSc patients compared to HCs (40.7% vs 28.15%, p=0.10).The percentage of CD21lowCD32low B cells was significantly increased in patients with DUs (23.82%) compared to HCs (4.43%, p=0.009) and to patients without DUs (4.39%, p = 0.015). CD21lowCD32low B cells were also significantly increased in the ILD group (28.43%) compared to HCs (4.43%, p=0.001) and to non-ILD group (6.25%, p=0.007) and in the anti-Topo I-positive patients (21.54%) compared to HCs (4.43%, p=0.012) and to anti-Topo I-negative patients (2.45%, p=0.022). No difference was found in the percentage of CD21lowCD32low B cells between men and women patients (14.61% vs 14.43%, p=0.98). Also, the percentage of CD21lowCD32low B cells did not show a statistically significant increase in all patients with SSc compared to HCs (14.47%, 4.43% p=0.08).CD32low B cells predominantly recognized Topo I compared to CD32+ B cells (mean difference 35.18, 95%CI 26.89 to 43.47, p=0.0003). Also, the expression of B cell receptors for Topo I was higher on CD32low B cells compared to CD32+ B cells. Conclusion: The increased percentage of CD21lowCD32low B cells in patients with main pathogenetic aspects of SSc (microangiopathy, ILD, and anti-Topo I autoantibodies) further supports the autoreactive nature of CD21lowCD32low B cells in SSc.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kourkouni, Evangeli
- Κουρκούνη, Ευαγγελή
Subjects
dc:subject × 17- Αυτοαντιδραστικά Β κύτταρα
- FcγRIIB
- Αντι - τοποισομεράση Ι αυτοαντίσωμα
- Διάμεση πνευμονική νόσος
- Μικροαγγειοπάθεια
- Συστηματική σκλήρυνση
- Autoreactive B cells
- Anti - topoisomerase I autoantibody
- Interstitial lung disease
- Microvasculopathy
- Systemic sclerosis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ρευματολογία
- Clinical Medicine
- Medical and Health Sciences
- Rheumatology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56801